0000899243-21-020171.txt : 20210520
0000899243-21-020171.hdr.sgml : 20210520
20210520165310
ACCESSION NUMBER: 0000899243-21-020171
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210518
FILED AS OF DATE: 20210520
DATE AS OF CHANGE: 20210520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dunlop A. Sinclair
CENTRAL INDEX KEY: 0001721108
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 21945150
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-18
0
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001721108
Dunlop A. Sinclair
C/O APELLIS PHARMACEUTICALS, INC
100 FIFTH AVENUE
WALTHAM
MA
02451
1
0
0
0
Common Stock
2021-05-18
4
S
0
64179
51.66
D
110549
I
See Footnote
Common Stock
2021-05-18
4
S
0
14216
52.63
D
96333
I
See Footnote
Common Stock
2021-05-18
4
S
0
36387
53.78
D
59946
I
See Footnote
Common Stock
2021-05-18
4
S
0
22318
54.57
D
37628
I
See Footnote
Common Stock
2021-05-18
4
S
0
1200
52.01
D
319479
I
See Footnote
Common Stock
2021-05-18
4
S
0
10388
53.50
D
309091
I
See Footnote
Common Stock
2021-05-18
4
S
0
800
54.02
D
308291
I
See Footnote
Common Stock
2021-05-19
4
S
0
7612
50.00
D
300679
I
See Footnote
Common Stock
2021-05-20
4
S
0
5773
48.10
D
31855
I
See Footnote
The reported transaction involved a sale of shares held by MASA Life Science Ventures, LP ("MASA"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.16 to $52.15. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4.
The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.16 to $53.12.
The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $54.15.
The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.16 to $54.94.
The reported transaction involved a sale of shares held by Epidarex Capital I, LP ("Epidarex"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.00 to $52.03. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (7) to this Form 4.
The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.00 to $53.99.
The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.00 to $54.04.
The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.00 to $48.50.
The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
/s/ David Watson, attorney-in-fact for A. Sinclair Dunlop
2021-05-20